For example, co-treatment with MEK inhibitors partly reversed the expression of PD-L1, due to an increased MAPK signaling, which characterizes melanoma cell lines with acquired resistance to BRAF inhibitors [88]. This evidence concerns the gene MAP2K7 and melanoma.